FY25 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FDA Office of Acquisitions and Grants Services
Contract Value
Not provided
Codes & Classification
Solicitation Number
FDABAA-25-00123_Award
NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Classification Code
AJ11
Additional Details
Documents2
The Food and Drug Administration (FDA), operating under the Department of Health and Human Services, has issued an award notice for its Fiscal Year 2025 Broad Agency Announcement (BAA) focused on the advanced research and development of regulatory science. This initiative, managed by the FDA Office of Acquisitions and Grants Services, aims to foster innovative research that supports the FDA’s mission to protect public health through the advancement of regulatory science.
The scope of this procurement encompasses research and development activities in biotechnology, specifically excluding nanobiotechnology, as classified under NAICS Code 541714. The Product Service Code associated with this opportunity is AJ11, which pertains to general research and development in the life sciences. The place of performance for awarded contracts is Silver Spring, Maryland, reflecting the FDA’s central location for scientific and regulatory activities.
A total of 15 contracts have been awarded under this BAA for FY25, as detailed in the attached spreadsheet referenced in the notice. Amendments to the original announcement have been made to update the list of awardees, ensuring transparency and accuracy in the reporting of contract outcomes. These awards represent a significant investment in projects that are expected to deliver advancements in regulatory science, supporting the FDA’s ongoing efforts to evaluate and oversee emerging technologies and products in the biotechnology sector.
The intended outcomes of this procurement activity include the development of new scientific tools, standards, and approaches that will enhance the FDA’s ability to assess the safety, efficacy, and quality of regulated products. Contractors are expected to deliver research findings, methodologies, and potentially new technologies that align with the FDA’s regulatory priorities.
The contracting entity for this opportunity is the FDA Office of Acquisitions and Grants Services, a federal office responsible for managing acquisitions and grant activities within the agency. The primary point of contact for this notice is Ian Weiss, who can be reached at [email protected] or by phone at 301-796-5728 for further information regarding the awarded contracts or future opportunities.
This procurement is classified as an award notice, indicating that the solicitation phase has concluded and contracts have been issued. There is no indication of set-aside requirements or special considerations in the provided information. The opportunity remains active as of the posting date, and interested parties can access further details, including the list of awardees, via the official notice URL on SAM.gov.
Contractors evaluating this opportunity should note that the focus is on advanced research in biotechnology relevant to regulatory science, with deliverables expected to contribute to the FDA’s scientific and regulatory capabilities. The location, classification codes, and agency context are consistent throughout the contract lifecycle, providing a stable framework for ongoing collaboration and research development.